The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The portfolio includes foundational patents on the production, composition, and commercial use of NR
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Subscribe To Our Newsletter & Stay Updated
